News

G2 Goldfields Showcases Strong Year-End Financial Results

G2 Goldfields Showcases Strong Year-End Financial Results

G2 Goldfields Announces Year-End Financial Results

G2 Goldfields Inc. (TSX:GTWO, OTCQX:GUYGF) has recently shared its financial results for the fourth quarter and the entire year ending May 31, 2024. The company has made its audited consolidated financial statements along with management’s discussion and analysis available for public review.

2024 Achievements

Dan Noone, President and CEO of G2 Goldfields, highlighted the company’s notable achievements throughout 2024. In January, G2 successfully raised around $22 million, followed by an additional $42 million through a private placement later in the year. This significant capital influx strengthens G2's financial position and enables the company to further develop its high-grade OKO project and pursue complementary exploration initiatives.

Overview of the Revised Technical Report

Alongside its financial results, G2 Goldfields has filed a revised independent technical report, which replaces the previous report dated May 17, 2024. This updated report, titled "NI 43-101 Technical Report and Mineral Resource Estimate for the Oko Gold Property in the Co-operative Republic of Guyana, South America," retains the effective date of March 27, 2024, even though it is dated June 20, 2024. Importantly, the mineral resource estimates remain unchanged from the announcement made on April 3, 2024.

Insights on the Revised Report

The Revised Technical Report was necessary to amend inaccuracies found in Figures 1.4, 14.14, and 25.4. These figures incorrectly displayed the grade-tonnage curve for the Ghanie zone underground, mistakenly replicating open pit data instead.

About G2 Goldfields Inc.

The G2 Goldfields team comprises seasoned professionals with a proven history of gold discovery in Guyana, including the financing and development of the region's largest gold mine, the Aurora Gold Mine. Their updated mineral resource estimate (MRE) for the Oko property includes:

Mineral Resource Estimates

The MRE encompasses a total combined open pit and underground resource for the Oko Main Zone (OMZ) of:

  • 495,000 oz. Au – Inferred, contained in 2,413,000 tonnes @ 6.38 g/t Au
  • 686,000 oz. Au – Indicated, contained in 2,368,000 tonnes @ 9.03 g/t Au

For the Ghanie Zone, the MRE indicates:

  • 604,000 oz. Au – Inferred, contained in 12,216,000 tonnes @ 1.54 g/t Au
  • 236,000 oz. Au – Indicated, contained in 3,344,000 tonnes @ 2.20 g/t Au

Micon International Limited prepared the MRE, which shows that the updated resources are located within 500 meters of the surface. The Oko district remains a significant alluvial goldfield, reflecting ongoing exploration success since the 1870s.

Validation of Findings by Experts

All scientific and technical findings presented in the news release have been reviewed and approved by Dan Noone, the CEO of G2 Goldfields Inc., who is recognized as a “qualified person” in accordance with National Instrument 43-101 regulations. Mr. Noone holds a B.Sc. in Geology and an MBA and is a member of the Australian Institute of Geoscientists.

Contact Information

For any further inquiries, please contact:

Dan Noone

CEO

+1.416.628.5904

Email: news@g2goldfields.com

Frequently Asked Questions

1. What are the key financial highlights for G2 Goldfields in 2024?

G2 Goldfields raised approximately $22 million in January and completed a $42 million private placement in August, marking significant financial growth.

2. What does the revised technical report entail?

The revised technical report provides updates to earlier figures and maintains the previous mineral resource estimates, enhancing data accuracy.

3. Who prepared the mineral resource estimate for the OKO project?

The mineral resource estimate was prepared by Micon International Limited, presenting significant potential in the Oko district.

4. How does G2 Goldfields validate its scientific findings?

Scientific and technical information is validated and approved by Dan Noone, the company's CEO, ensuring compliance with regulatory standards.

5. What is the best way to contact G2 Goldfields for inquiries?

Inquiries can be sent to Dan Noone via email at news@g2goldfields.com or by calling +1.416.628.5904.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 30

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 25

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 45

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 59

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 41

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 38

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 34

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading

Top 5 Most Recently Viewed Articles

Genesys Celebrates Global Recognition as a Top Workplace

Updated Category News Views 50

Genesys Achieves Global Recognition for Workplace Excellence Genesys, a renowned leader in AI-driven experience orchestration, has been proudly certified as a Great Place to Work. This significant accomplishment reflects the overwhelming sentiment from its employees, with a remarkable 90% affirming that Genesys is indeed a fantastic workplace. This statistic represents a...

Continue Reading
Class Action Alert for Twitter Stockholders: Important Updates

Updated Category News Views 198

Understanding the Class Action Lawsuit for Twitter, Inc. Stockholders A significant class action lawsuit has been initiated for individuals and entities who traded Twitter, Inc. stock or options during a specified period. This legal action has garnered substantial attention as it affects numerous investors who believe they suffered losses due to alleged misconduct. Key...

Continue Reading
Rhythm Pharmaceuticals Advances IMCIVREE® for Young Patients

Updated Category News Views 180

Rhythm Pharmaceuticals Receives FDA Acceptance for Priority Review Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company, has announced that the FDA has accepted its supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide). This application has been designated for Priority Review by the FDA, which suggests that patients may gain timely...

Continue Reading
Understanding Market Trends Impacting NCR Atleos Corp's Future

Updated Category News Views 59

Market Sentiment Surrounding NCR Atleos Corp NCR Atleos Corp (NYSE: NATL) has recently caught the attention of investors as its short interest percentage has experienced a notable increase. Currently, approximately 3.76% of the company's shares have been sold short, which translates to about 3.01 million shares. This figure indicates that roughly 6.35% of all regular...

Continue Reading
Leslie’s, Inc. Reports Q2 Fiscal 2025 Earnings and Key Insights

Updated Category News Views 346

Financial Highlights from Leslie’s, Inc. In light of recent developments, Leslie’s, Inc. (NASDAQ: LESL), the premier name in pool and spa care in the U.S., has unveiled its financial results for the second quarter of fiscal year 2025. The company is dedicated to serving both residential and professional customers with quality products and exceptional service. CEO...

Continue Reading